# A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration

> **NCT02181517** · PHASE2 · COMPLETED · sponsor: **Allergan** · enrollment: 25 (actual)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** abicipar pegol
- **DRUG:** ranibizumab
- **OTHER:** sham procedure

## Key facts

- **NCT ID:** NCT02181517
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2016-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02181517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02181517, "A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02181517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*